Respiratory syncytial virus vaccines: An update on those in the immediate pipeline

Susanna Esposito, Giada Di Pietro

Research output: Contribution to journalReview articlepeer-review


Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development. Among the candidates in clinical trials, nanoparticle and subunit vaccines seem to be the most promising for pregnant women and the elderly, whereas live-attenuated or vector-based vaccines appear to be optimal for the pediatric population.

Original languageEnglish
Pages (from-to)1479-1490
Number of pages12
JournalFuture Microbiology
Issue number11
Publication statusPublished - Nov 1 2016


  • prevention
  • RSV
  • vaccines

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'Respiratory syncytial virus vaccines: An update on those in the immediate pipeline'. Together they form a unique fingerprint.

Cite this